Yumen Qianhua Pharmaceutical Co., Ltd. (Changzhou Tianhua Pharmaceutical Co., Ltd.) was formerly the Jintan Tianhua Chemical New Technology Research Institute founded in 1995, with fixed assets of 80 million yuan and a total area of 40,000 square meters. The company currently has more than 60 employees, including more than 20 technical personnel, and is adjacent to Shanghai and Nanjing with convenient transportation.

Tianhua Pharmaceutical is an emerging integrated scientific, industrial and trade pharmaceutical API and intermediate manufacturer with independent import and export rights, exporting to Europe, America, Japan and Southeast Asia. It not only has its own R&D team, but also has established long-term cooperative relationships with well-known domestic and foreign universities and research institutions. The company currently has more than 70 reaction kettles, GMP API production lines and multiple sets of high-precision analytical instruments, and can complete a variety of synthetic reactions such as hydrogenation, Grignard, cyanation and halogenation.

In July 2005, it passed the GB/T19001-2000 quality management system certification; in December 2007, it passed the GB/T24001-2004 environmental management system certification, and fully implemented GMP standard management. On March 4, 2011, it obtained the Japanese API Foreign Manufacturer Confirmation Certificate. In June 2011, it passed the FDA on-site compliance inspection, and tetracaine hydrochloride, tetracaine and terbinafine hydrochloride successfully registered with the FDA, possessing NDC numbers and corresponding DMF and EDMF documents.

Tianhua Pharmaceutical has become an important supplier of pharmaceutical and chemical intermediates for large and medium-sized domestic and foreign pharmaceutical enterprises. Among them, diethyl iminodiacetate, benzamidine hydrochloride salt, trichloropropylamine hydrochloride salt, diphenylpropionic acid and other products have an annual export value of more than 6 million US dollars, winning the praise and favor of many companies.

In 2021, Yumen Qianhua Pharmaceutical Co., Ltd. was newly established in Yumen, Gansu. The company covers an area of 136 mu, with a designed annual output of 1,000 tons of APIs and intermediates. It has four synthesis workshops and two API refining, drying and packing workshops. It is planned to install 200 reaction kettles with a capacity of 2000-5000L, and more than 50 centrifuges and drying equipment in total. At present, the first-phase project is nearly completed, and it is expected to be put into operation in the second half of 2022.

Changzhou Tianhua Pharmaceutical has always adhered to high standards and strict requirements for many years. Taking international standards as the benchmark in every link of development, production and sales, it strengthens quality control and quality assurance, provides excellent services and products for customers, and creates value for customers! In October 2011, it was awarded the title of "High-tech Enterprise", and has maintained a 3A-level credit enterprise for many years.